Lynparza 50mg


Lynparza 50mg is a type of targeted therapy called a PARP (oral poly (adenosine diphosphate–ribose) polymerase inhibitor)which has promising anti neoplasticaction in patients with metastatic breast cancer and a germline BRCA mutation.
Lynparza 50mg capsule is an enzyme included in DNA repair and will act against cancers in people with hereditary BRCA1 or BRCA2 mutations, which involve some ovarian, breast and prostate cancer
Lynparza 50mg is a prescription drug which used under the supervision of medical practioners

INDICATION


Lynparza 50mg capsule is used for the treatment in patients with first line maintenance BRCAm advanced ovarian cancer
Lynparza 50mg is used for the treatment in patients with maintenance recurrent ovarian cancer.
Lynparza 50mg capsule is used for the treatment in patients withadvanced gBRCAm ovarian cancer
Lynparza 50mg is indicated for the treatment in patients with HER2 – negative metastatic breast cancer.

DOSAGE

Ovarian cancer :

Maintenance treatment of recurrent ovarian cancer
The tablet usual dose is 300mg (two 150mg – mg tablets) PO BID
Continue treatment until disease progression or unacceptable toxicity
Monotherapy for advanced BRCA – mutated ovarian cancer
The tablet usual dose is 300mg (two 150mg – mg tablets) PO BID
The capsules usual dose is 400mg (eight 50mg- mg capsules) PO BID
Continue treatment until disease progression or unacceptable toxicity.
Maintenancetreatment for advanced BRCA-mutated ovarian cancer
The tablet usual dose is 300mg (two 150mg – mg tablets) PO BID
Follow the treatment until disease progression, undesirable toxicity or completion of 2 years of treatment
Finishing of 2 years of treatment
• Patients with full response (no radiologic evidence): discontinue treatment
• Patients with indication of disease and may asset from continuous treatment: cure beyond 2 years.

MECHANISM


Olaparib belongs to targeted therapy. Olaparib is also called as poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, involving PARP1, PARP2, and PARP3. PARP enzymes are containing in DNA transcription, cell cycle regulation, and DNA repair.
Olaparib belongs to potent oral PARP inhibitor which induces synthetic fatality in BRCA 1/2 deficient tumor cells via the formation of double-stranded DNA cutsthat cannot be accurately repaired, which causesdivision of cellular homeostasis and cell death

ADME


Absorption: Maximum plasma concentration 1 to 3 hours
Distribution: volume of distribution 167 +/-196 L, plasma protein binding is 82%
Metabolism: Primarily metabolised by CYP3A4
Elimination: Excreted through the urine 44% and 42% through the feces.
Half – life of Lynparza 11.9 hours

PRECAUTION


• Haematological toxicity will cause in patients treated with Lynparza contain diagnoses or findings of generally mild or moderate anaemia, neutropenia, thrombocytopenia and lymphopenia.
• When Lynparza 50mg capsule monotherapy administrated to patient the incidence of myelodysplastic syndrome will occur. • On basis of mechanism of action (PARP inhibition), Lynparza could cause risk to fetal when administered to a pregnant woman.
• Lynparza combination with strong or moderate CYP3A inhibitors is not recommended.
Lynparza 50mg capsule
Lynparza 50mg

DRUG INTERACTION

Concomitant use with myelosuppressive anticancer agents contains DNA damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity.
Combination of strong CYP3A inhibitors (itraconazole, telithromycin, clarithromycin,) will increase Olaparib plasma concentration.
Lynparza 50mgcombination with strong CYP3A inducers (itraconazole, telithromycin, clarithromycin,) will decrease Olaparib plasma concentration.

CONTRAINDICATION

None.

MISSED DOSE


If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule.
Consult doctors regarding missed dose.

STORAGE

Store at 20℃ to 25℃

SIDE EFFECTS

Common side effects for patients taking Olaparib :

• Decreased white blood cell count
• Abdominal pain
• Vomiting
• Upper respiratory tract infection
• Anemia
• Decreased neutrophils
• Musculoskeletal pain
• Diarrhea
• Decreased platelet count
• Decreased Haemoglobin
• Nausea
• Fatigue (including weakness)
• Increased serum creatinine
• Myalgia
• Headache
• Skin rash
• Back pain
• Taste changes
• Cough
• Swelling
• Dizziness
• Constipation
• Urinary tract infection
• Heartburn
• loss of appetite
• Shortness of breath

Contact Details


Phone : +91-9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Comments

Post a Comment

Popular posts from this blog

Opdyta 40mg injection | Apple pharmaceuticals

Image
Opdyta 40mg Opdyta 40mg is prescription drug which is used under supervision of doctor Opdyta 40mg injection belongs to human monoclonal antibody which stops the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Opdyta 40mg is an IgG4 kappa immunoglobulin which has a calculated molecular mass of 146 kDa. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line. Opdyta 40mg is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells. INDICATION Opdyta 40mg is indicated for the treatment of patients having : • Melanoma • Non-Small Cell Lung Cancer • Kidney (Renal Cell) Cancer DOSAGE Opdyta recommended dosage for unresectable or metastatic melanoma: As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity  With ipilimum
Read more

Opdyta 100 мг для инъекций | Apple pharmaceuticals

Image
Опдита 100 мг Opdyta 100 мг - это рецептурный препарат, который используется под наблюдением врача Инъекция Opdyta 100 мг относится к человеческому моноклональному антителу, которое останавливает взаимодействие между PD-1 и его лигандами, PD-L1 и PD-L2. Opdyta 100 мг - это каппа-иммуноглобулин IgG4, который имеет расчетную молекулярную массу 146 кДа. Он экспрессируется в клеточной линии рекомбинантных клеток яичника китайского хомячка (СНО). Opdyta 100 мг инъекций также известен как ингибитор иммунной контрольной точки. Иногда эти препараты называют таргетной терапией, потому что они нацелены на специфические белки (рецепторы) на поверхности клеток. ПОКАЗАНИЯ Opdyta 100 мг показан для лечения пациентов, имеющих: • Меланома • немелкоклеточный рак легких • Рак почек (почечных клеток) ДОЗИРОВКА Opdyta 100 мг рекомендуемая дозировка для неоперабельной или метастатической меланомы: В качестве одного средства используется либо 240 мг каждые 2 недели, либо 480 мг каждые 4
Read more

Ленватиниб 10 мг

Image
Ленватиниб 10 мг Ленватиниб 10 мг также известен как ингибитор тирозинкиназы. Капсула Lenvatinib 10 мг предназначается для раковых клеток. Ленватиниб 10 мг хорошо усваивается. В котором еда не влияет на диапазон поглощения, но снижает скорость. Капсула Lenvatinib 10 мг , которая является отпускаемым по рецепту лекарством, используемой под надлежащим руководством медицинского онколога. ПОКАЗАНИЯ • Показано для лечения рака щитовидной железы, который нельзя лечить радиоактивным йодом. • Показано в сочетании с эверолимусом для лечения прогрессирующей почечной карциномы, при которой другие лекарственные средства оказались неэффективными. • Показано для лечения гепатоцеллюлярного первичного рака печени ДОЗИРОВКА Рекомендованная доза дифференцированного рака щитовидной железы - 24 мг Ленватиниба, она назначается в виде двух капсул по 10 мг и одной капсулы по 4 мг, принимаемых перорально, один раз в день, вместе с пищей или без нее. Рекомендуемая доза почечно-клеточного ра
Read more